Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death  by Alvarez, Alejandra et al.
Inhibition of tau phosphorylating protein kinase cdk5 prevents
L-amyloid-induced neuronal death
Alejandra Alvareza;*, Rodrigo Toroa, Alfredo Ca¤ceresb, Ricardo B. Maccionia
a Laboratory of Cellular and Molecular Biology, Faculty of Sciences, University of Chile and International Center for Cancer and Developmental
Biology (ICC), Las Palmeras 3425, Nì un‹oa, Santiago, Chile
b Instituto Mercedes y Mart|¤n Ferreyra, Co¤rdoba, Argentina
Received 13 May 1999; received in revised form 10 September 1999
Abstract The key target of this study was the tau protein
kinase II system (TPK II) involving the catalytic subunit cdk5
and the regulatory component p35. TPK II is one of the tau
phosphorylating systems in neuronal cells, thus regulating its
functions in the cytoskeletal dynamics and the extension of
neuronal processes. This research led to demonstration that the
treatment of rat hippocampal cells in culture with fibrillary
L-amyloid (AL) results in a significant increase of the cdk5
enzymatic activity. Interestingly, the data also showed that the
neurotoxic effect of 1^20 WM AL on primary cultures markedly
diminished with co-incubation of hippocampal cells with the
amyloid fibers plus the cdk5 inhibitor butyrolactone I. This
inhibitor protected brain cells against AL-induced cell death in a
concentration dependent fashion. Moreover, death was also
prevented by a cdk5 antisense probe, but not by an oligonucleo-
tide with a random sequence. The cdk5 antisense also reduced
neuronal expression of cdk5 compared with the random
oligonucleotide. The studies indicate that cdk5 plays a major
role in the molecular path leading to the neurodegenerative
process triggered by the amyloid fibers in primary cultures of rat
hippocampal neurons. These findings are of interest in the
context of the pathogenesis of Alzheimer’s disease.
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1. Introduction
Alzheimer’s disease (AD) corresponds to one of the most
common types of senile dementia in adults older than 65
years. This disease is characterized by cognitive disorders as-
sociated with a loss of memory and orientation and deterio-
ration of the intellectual capacity of patients. Two major his-
tological lesions are observed in AD brains, associated with a
neuronal loss: (i) at the intracellular level, formation of neuro-
¢brillary tangles (NFTs) composed of paired helical ¢laments
(PHFs), composed of hyperphosphorylated tau [1,2], and (ii)
at the extracellular level by senile plaques formed by the ¢-
brillary L-amyloid (AL) [3].
NFTs are mainly deposited in cellular bodies of neurons,
apical dendrites, even though lesions are also found in ¢la-
ments of the neuropil and distrophic neurites around the core
of amyloid plaques [1]. PHFs consist of two coiled ¢laments
resulting from self-polymerization of tau subunits arranged in
a helical supramolecular structure of 10^20 nm in diameter
[4]. Tau, one of the most relevant MAPs, corresponds to a set
of six major isoforms containing around 352^441 amino acids,
products of the alternative splicing of a single gene [5]. These
isoforms di¡er from each other for the presence of either three
or four microtubule (MT) binding motifs [6] and a variable
number of 29 amino acid inserts towards the N-terminal moi-
ety [7,8]. Tau co-localizes with MTs and its major cell role is
modulating MT assembly and their stabilization in neurons
[9], although a role for tau in directing neuritogenesis has also
been reported [10]. Tau of the Alzheimer’s type contains 3^4
repeats, shows three major bands in the sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) system
and is highly insoluble [11,12].
Tau participates in two apparently di¡erent functions: to
induce MT assembly under normal conditions and to self-
associate under pathological conditions like those of AD
and other dementia. In this context, tau hyperphosphoryla-
tions determined by the e¡ects of di¡erent protein kinases and
phosphatases causes conformational changes, thus a¡ecting its
assembling capacity and interactions with tubulin [13,14]. Sev-
eral phosphorylation sites have been identi¢ed on the tau
molecule, including a site on the ¢rst tau repeat [15]. Anom-
alous phosphorylations on tau appear to be involved in its
abnormal self-aggregation into PHFs, leading to a loss of
the normal neuronal functions [16].
Among kinases involved in tau modi¢cations leading to
PHFs, two are the most relevant: tau protein kinase I (TPK
I) also named glycogen synthase kinase 3L and tau kinase II
(TPK II) [17,18]. TPK II is a complex of two subunits : a
catalytic component of 33 kDa (cdk5) and the regulatory
subunit of 23 kDa (p35) derived from proteolytic cleavage
of a 34 kDa precursor [19]. The neuron-speci¢c activator
p35 is involved in axonal growth [20]. TPK II is a proline-
directed Ser/Thr kinase that contributes to the phosphoryla-
tion of human tau on Ser202, Thr205, Ser235 and Ser404 [18].
The abnormally phosphorylated tau contains PHF epitopes.
TPK I phosphorylates tau at four distinct sites : Ser199, Thr231,
Ser396 and Ser413 [21]. These sites correspond to those phos-
phorylated in the PHF-tau puri¢ed from the AD brains [22].
The initial phosphorylation of tau with TPK II appears to
stimulate tau modi¢cations by the TPK I/GSK3L kinase sys-
tem [23,24]. The results showed that AL induces an increase in
protein kinase activity of cdk5 on hippocampal cells, a phe-
nomenon associated with neuronal death. It was noteworthy
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to observe that butyrolactone I, a cdk5 inhibitor [25], pre-
vented neuronal death caused by the ¢brillary AL. Neurons
were protected from the toxic e¡ects of AL by treatment of
cultures with cdk5 antisense oligonucleotides. The result sug-
gest that in rat hippocampal neurons, cdk5 participates in the
process of cell death triggered by AL, which could contribute
to the formation of NFT.
2. Materials and methods
2.1. Hippocampal cultures
Primary rat hippocampal cultures were prepared as described
[26,27]. Brie£y, hippocampi from Sprague-Dawley rats at embryonic
day 18 were dissected in Ca2/Mg2-free Hank’s balanced salt solu-
tion (HBSS, Gibco 14180-020) with 10 mM HEPES, pH 7.4, and 0.5%
glucose and rinsed twice with HBSS by allowing for the tissue to settle
to the bottom of the tube. After the second wash, the tissue was
resuspended in HBSS containing 0.25% trypsin (Gibco 25095-019)
and incubated for 5 min at 37‡C. After three rinses with HBSS, the
tissue was mechanically dissociated in minimal essential medium
(MEM, Gibco 61100-053; Earle’s salt, sodium bicarbonate-bu¡ered,
600 mg/l glucose), supplemented with 10% heat-inactivated fetal bo-
vine serum, 50 U/ml penicillin, 50 mg/ml streptomycin, 1 mM sodium
pyruvate and 2 mM L-glutamine (MEM-10), by gentle passage
through pasteur pipettes. Undisrupted tissue fragments were allowed
to settle, cells in suspension were transferred to a new tube and viable
cells were counted using 0.2% trypan blue. Cells were initially plated
in MEM-10 media and maintained at 37‡C in a humid atmosphere
with 5% CO2/95% air. Three h after plating, media MEM-10 was
removed and serum-free medium N2/MEM added (MEM supple-
mented with 2 mM L-glutamine, 750 mg/l glucose, 100 WM putrescine,
20 nM progesterone, 30 nM selenium dioxide, 100 Wg/ml transferrin,
5 Wg/ml insulin, 1 mM sodium pyruvate and 0.1% ovalbumin).
2.2. Cytotoxicity assays
For cytotoxicity assays, the hippocampal cells were seeded in poly-
lysine-coated 96 well plates at 2.0U104 cells/100 Wl per well and main-
tained in N2/MEM without phenol red media. After day 4 of in vitro
culture, neurons were treated with the amyloid ¢brils with or without
butyrolactone I or N2/MEM media (control) were added to the wells
at di¡erent concentrations in a ¢nal volume of 10 Wl. Cells were
incubated for 24 h at 37‡C, after which the cell viability was measured
by the modi¢ed 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay [28]. This involves determining mitochondrial
dehydrogenase activity in intact cells by incubation for 4 h at 37‡C
with MTT (10 Wl of 5 mg/ml MTT solution per well). The reaction
was stopped by addition of cell lysis bu¡er (50% dimethylformamide
and 20% SDS, pH 7.4). vA values at 540^650 nm were determined the
following day, using an automatic microtiter plate reader (Metertech
4960) and the results were expressed as a percentage of control.
2.3. Microscopy of £uorescently stained cells
Neurons were plated at 1U106 cells/cm2 on polylysine-coated cov-
erslips. After 4 days in N2/MEM media, cells were exposed to AL
¢brils in the presence or the absence of butyrolactone I and incubated
for 24 h. Then, the cells were incubated for 30 min with 20 WM
propidium iodide (PI) and 150 nM calcein acetoxymethyl ester (cal-
cein-AM) (Molecular Probes, Eugene, OR, USA), rinsed and visual-
ized by £uorescence microscopy (Zeiss Axiovert). Calcein-AM labels
viable cells, whereas PI has access only to cells with plasma membrane
damage and accumulates in the nucleus.
2.4. Immunoprecipitation and assay of cdk5 activity
Neurons were plated at 1U106 cells/cm2 on polylysine-coated 35
mm dishes. After 4 days in N2/MEM media, the cells were exposed to
20 WM AL ¢brils in N2/MEM for 24 h. Hippocampal cells were lysed
in bu¡er RIPA (50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 Wg/ml PMSF,
2 Wg/ml aprotinin, 2 WM leupeptin and 1 Wg/ml pepstatin). Two-hun-
dred Wg of total cellular protein was used for immunoprecipitation
with anti-cdk5 antibody (Santa Cruz, CA, USA) at a ¢nal dilution of
1:50. For an in vitro kinase assay, the immunoprecipitates were rinsed
three times with RIPA bu¡er and one time with kinase bu¡er (50 mM
HEPES, 10 mM MgCl2, 5 mM MnCl2, 1 mM DTT) plus 1 WM cold
ATP. The washed beads were incubated with kinase bu¡er containing
2.5 Wg of histone H1 or 20 Wg microtubular protein or 4 Wg puri¢ed
tau [6] plus 5 WCi [32P]ATP in a ¢nal volume of 50 Wl for 30 min
at 24‡C. Enzyme assays using the synthetic tau peptide
RTPPKS235PSSAKSR as a kinase substrate were also carried out.
After incubation, 50 Wl of 2ULaemmli sample bu¡er [29] was added
to each sample and they were analyzed by SDS-PAGE and autora-
diography [10].
2.5. Preparation of AL ¢brils
Synthetic peptide AL1ÿ40, including residues 1^40 of the human AL
sequence were purchased from Chiron Corporation (Emereville, CA,
USA). The AL1ÿ40 peptide was incubated in a stirring aggregation
assay as described [30]. Stock solutions were prepared by dissolving
lyophilized aliquots of AL peptide in dimethylsulfoxide (DMSO) at 15
mg/ml (3.5 mM). Aliquots of peptide stock solution (70 nmol in 20 Wl
DMSO) were added to PBS, pH 7.2, to give a ¢nal volume of 0.725
ml. The solution was stirred continuously and aggregation was meas-
ured by the turbidity at 400 nm using bu¡er as a blank. After 6 h
incubation under stirring, the solution was incubated for 4 days after
which the formed aggregates were analyzed by electron microscopy.
The amyloid nature of ¢brils was evaluated by thio£avine T using
£uorescence microscopy [31]. The AL ¢brils were concentrated by
centrifugation (14 000 rpm for 30 min) and resuspended at 1 mg/ml
in N2/MEM media, the AL concentration was evaluated by the BCA
protein assay (Pierce) as described by Smith et al. [32]. Butyrolactone
I (Calbiochem, La Jolla, CA, USA) prepared in 10 mM DMSO was
added with AL ¢brils at the concentrations indicated and ¢nal DMSO
remained less than 0.04%.
2.6. Antisense oligonucleotides
Antisense phosphorothioate oligonucleotide (S-modi¢ed) RK2 de-
scribed by Pigino et al. [10] was used in the present study. This oli-
gonucleotide consists of the sequence 5P-GCATCGCAGCGGCCA-3P
and it is the inverse complement of nucleotides +83/+97 of the cDNA
for cdk5 and was purchased from Quality Controlled Biochemicals
(Hopkinton, MA, USA). The antisense oligonucleotide was pre-incu-
bated with 2 Wl of Lipofectin Reagent (1 mg/ml, Gibco BRL, Gai-
thersburg, MD, USA) diluted in 100 Wl of serum-free medium. The
resulting oligonucleotide suspension was then added to primary hip-
pocampal cultures that were grown for 4 days. Four pulses of oligo-
nucleotide (1 WM each) were added every 6 h within a period of 24 h.
Control cultures were treated with the same concentration of a
scrambled oligonucleotide sequence. Simultaneously with the third
pulse of the oligonucleotide (after 12 h treatment), AL ¢brils (1^10
WM) were added to hippocampal cells, after the cell viability was
evaluated. The e¡ects of the cdk5 antisense on expression of the
enzyme were assessed by Western blot analysis [20] of the immuno-
reactive cdk5 in both AL-treated and non-treated paired samples.
2.7. Statistical analyses
The program Graph Pad Prism was used for all statistical analyses
and evaluation of tests of signi¢cance during this study.
3. Results
The expression and activity of cdk5 in hippocampal neu-
rons. Rat primary hippocampal cultures have proved to be an
appropriate model for studying amyloid toxicity [27,33]. The
involvement of cytoskeletal proteins in the morphological
changes associated with neuronal death induced by the amy-
loid ¢brils have been investigated in these cells [34,35]. On the
other hand, protein kinase TPK II appears to be a regulatory
element of the microtubular cytoskeleton, playing a critical
role in neurites [10]. We have taken advantage of this model
system to obtain information about the relationships between
TPK II and the cellular changes in neuronal cells exposed to
amyloid. The cdk5 levels in hippocampal cultures were ana-
lyzed by using a rabbit polyclonal antibody against cdk5 as
shown in Fig. 1A. The antibody recognized a single band of
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approximately 35 kDa, when whole cell homogenates were
resolved in SDS-PAGE, blotted and immunostained with
anti-cdk5 antibody (Fig. 1A, lane 1). A higher level of cdk5
staining was observed in cells incubated with AL (Fig. 1A,
lane 2). Western blot analysis revealed that the hippocampal
neurons express cdk5 after 4 days of plating the cells and that
a relatively small increase in its levels occurred when cells were
exposed to AL ¢brils (15 WM) by 24 h. By contrast, immuno-
precipitates of cdk5 from hippocampal cells incubated with
AL ¢brils showed that the amyloid induced a signi¢cant in-
crease in cdk5 kinase activity (Fig. 1B, lanes 1 and 2), using
histone H1 as a substrate. Furthermore, a signi¢cant increase
in cdk5 activity was observed in cdk5 immunoprecipitates of
the cells exposed to amyloid ¢brils, when microtubular pro-
tein (Fig. 1C, lanes 1 and 2) or pure tau (Fig. 1D, lanes 1 and
2) were used as a substrate. Additional con¢rmation was ob-
tained by an experiment showing an increased phosphoryla-
tion of the synthetic tau peptide RTPPKS235PSSAKSR as
related to AL-induced cdk5 activation (Fig. 1E, lanes 1 and
2). Concomitant with this e¡ect in activating cdk5, AL trig-
Fig. 1. E¡ects of AL ¢brils in the activity and expression of cdk5 in cultured hippocampal neurons. The expression of cdk5 in the cells was re-
vealed by Western blot analysis of cell homogenates reacted with the antibody anti-cdk5 (1:1000). Twenty Wg of total protein was loaded in
each well. Samples were obtained at 24 h after the treatment (A, lane 1, control cells ; lane 2, cells exposed to 15 WM AL ¢brils). The cdk5 ki-
nase activity in hippocampal neurons exposed to 15 WM AL ¢brils was analyzed after immunoprecipitation of cell homogenates (200 Wg/sam-
ple), followed by incubation with [32P]ATP either in the presence of H1 histone as a substrate (B, lane 1 untreated control; lane 2, treated with
15 mM AL ¢brils) or in the presence of microtubular protein as substrate (C, lane 1, control; lane 2, AL-treated) or using puri¢ed tau as a
substrate (D, lane 1, control; lane 2, AL-treated sample). Furthermore, cdk5 activity from hippocampal cells was assessed by using the tau pep-
tide RTPPKS235PSSAKSR as a substrate (E, lane 1, untreated control; lane 2, treated with AL).
Fig. 2. E¡ects of AL and butyrolactone on the morphological integrity of primary neurons. AL peptide was added in the presence or the ab-
sence of butyrolactone I and cells were analyzed 24 h later by £uorescence microscopy after labelling with calcein-AM and PI. (A) Control neu-
rons, (B) cells only treated with 5 WM butyrolactone, (C) cells treated with 10 WM AL, (D) cells treated with 5 WM butyrolactone I plus 10 WM
AL. Images are representatives of many cultures in which multiple ¢elds were analyzed under each experimental condition. Higher magni¢ca-
tions of cells treated with AL (E) and cells treated with AL plus butyrolactone I (F) are also shown.
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gered morphological changes of neurons and neuronal death,
in a peptide concentration-dependent fashion. In addition,
studies were carried out to evaluate expression of cdc2, cdk4
and cdk6 and none of these kinases were detected in the rat
hippocampal cells.
In this context, it was of utmost interest to examine the
e¡ects of butyrolactone, a cdk5 inhibitor, on the morphology
of AL-exposed cells. Neurons from a single preparation were
plated at the same density, grown for 4 days and exposed to
AL with or without butyrolactone I (5 WM) for 24 h and
visualized using calcein/PI as shown in Fig. 2. Control cells
retained the calcein dye (green) and showed extensive neuritic
processes (Fig. 2A). No labelling with PI (red) was observed
in these cultures, indicating that almost no dead cells were
present. After AL exposure for 24 h, neuritic processes became
shortened or disappeared and a signi¢cant proportion of PI-
labelled death cells was observed (Fig. 2C,E). However, when
butyrolactone was added to cultures with AL, degenerative
changes were much less evident (Fig. 2D), many neurons still
had normal, long processes as shown at higher magni¢cation
(Fig. 2F). When butyrolactone was added alone, cells were
indistinguishable from the controls (Fig. 2B). These patterns
are representative of several experiments (n = 5). The percen-
tages of surviving neurons after AL treatment were estimated
with the calcein/PI assay: neurons treated with 10 WM AL had
survival rates of 30%, however, viability of neurons treated
with 10 WM AL in the presence of butyrolactone was over
60%. Butyrolactone I alone for 24 h did not decrease viability.
In order to correlate changes in morphology and viability
with the general metabolic state of the cell, MTT reduction
was assayed. Fig. 3 shows the concentration-dependent neuro-
toxic response of hippocampal cells incubated with increasing
concentrations of AL ¢brils alone or in the presence of the
cdk5 inhibitor. The increase in the AL ¢brils concentration
incremented cell death, as re£ected by the gradual decrease
in MTT reduction. However, MTT associated with neuronal
survival for cells exposed to AL in the presence of 5 WM
butyrolactone was much higher, as revealed by the two-tail
Student t-test of signi¢cance, with n = 5. Butyrolactone pro-
tects hippocampal cells from neuronal death induced by AL.
Fig. 4 shows the concentration-dependent protective e¡ects of
butyrolactone I on hippocampal cells against AL-induced tox-
icity. Increasing concentrations of butyrolactone I increased
the viability of AL ¢brils-treated neurons, the toxic e¡ect of
the AL ¢brils was almost completely blocked by 20 WM bu-
tyrolactone. As control, the inhibitor added in the absence of
AL did not modify cell survival.
To further analyze whether cdk5 was involved in the events
leading to neuronal death, experiments were conducted with a
cdk5 antisense oligonucleotide, that inhibits cdk5 expression
[10]. In the negative control, the treatment of rat hippocampal
cells cultured with either 1 or 10 WM AL ¢brils, with an oli-
gonucleotide with a scrambled sequence (4 WM) did not pre-
vent neurotoxicity caused by the amyloid. However, in the
presence of AL ¢brils plus cdk5 antisense oligonucleotide (4
WM), neurotoxicity was signi¢cantly reduced (Fig. 5). The
protection e¡ect of the antisense against AL-promoted neuro-
nal death was correlated with a decrease in cdk5 expression by
more than 50% (Fig. 5, insert, lane 3) as compared with con-
trols incubated with AL but in the absence of antisense (lane
1) or controls treated with a scrambled oligonucleotide (lane
2).
4. Discussion
The amyloidogenic theory states that AL is a factor trigger-
ing a series of molecular events leading to neuronal death [3].
On the other hand, it has been described that AL has a neuro-
toxic e¡ect on neuronal cell lines and that this e¡ect is directly
related with the level of aggregation of the amyloid [33]. It
was also reported that neuronal cells treated with AL result in
a selective phosphorylation of speci¢c epitopes on PHFs [35].
The focus of the present study was to explore the links be-
tween the action of ¢brillary AL and tau phosphorylations, in
the context of molecular changes leading to neuronal death.
Previous studies have shown that amyloid ¢brils, but not
amorphous aggregates of AL, are toxic to neuronal cells in
culture [33] and the existence of a strong correlation between
AL neurotoxicity and the aggregation state of the AL peptide
Fig. 3. E¡ects of butyrolactone I on AL-induced neurotoxicity in
hippocampal cell cultures. Cultures were treated with increasing
concentrations of amyloid ¢brils. AL ¢brils alone (b), AL ¢brils
plus 5 WM butyrolactone I (a). Cell viability was evaluated using
the MTT reduction assay. Cell viability after treatment was meas-
ured by the MTT reduction assay (n = 5). The two-tail t-test re-
vealed signi¢cant di¡erences between data of cells treated with AL
and those treated with AL plus butyrolactone. **P6 0.001 by non-
paired Student’s t-test.
Fig. 4. Concentration-dependent protective e¡ects of butyrolactone I
on hippocampal cells against AL-induced toxicity. Increasing con-
centrations of butyrolactone I (b), increased MTT reduction as an
expression of viability of neurons treated with AL. The toxic e¡ect
of the AL ¢brils diminished as the concentration of butyrolactone
(1^20 WM) increased. As a control, the inhibitor added in the ab-
sence of AL (a) did not modify cell survival. Data are expressed
with the respective S.D.s.
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[34,36]. In the present study, it was noteworthy that the addi-
tion of pre-formed amyloid ¢brils to neuronal cultures caused
an activation of protein kinase cdk5, as measured using his-
tone and tau as substrates. This protein kinase has been found
distributed in both the nucleus and cytoplasm of neurons
from normal and Alzheimer’s brains [37]. According with pre-
vious ¢ndings, Ser235 is a main residue phosphorylated by
cdk5 on human tau [38]. The present ¢ndings are of interest,
since they provide a suggestion that TPK II appears to medi-
ate the e¡ects of AL on neuronal tau behavior. In this context,
previous studies have shown that glycogen synthase kinase
(TPK I) seems to be involved in mediating AL-induced neuro-
toxicity [38]. The treatment with amyloid increased TPK I,
thus a¡ecting the neuronal tau capacity to interact with the
microtubular cytoskeleton [38]. On the other hand, TPK I
phosphorylates tau threonine-231 on a pT231-P bond, contain-
ing a proline residue susceptible to prolyl isomerization by
Pin-1 [39]. In the line of these observations, it has also been
reported that tau from COS cells transfected with GSK3L and
cdk5 activator (p35) exhibits phosphorylations at almost all
Alzheimer’s epitopes [22]. In this context, it is interesting to
point out that, in contrast with AL, the excitatory amino acid
glutamate and the drug colchicine appear to prevent anoma-
lous phosphorylations on tau in cortical neurons [40].
Besides the action of AL on tau phosphorylation, the
present studies show that direct blockage of cdk5 by the en-
zyme inhibitor, butyrolactone [25], or alterations on cdk5 ex-
pression by using an antisense probe for cdk5 [10] reduced
signi¢cantly the signs of neurotoxicity and prevented neuronal
death. Since no expression of other cdks was detected under
the present experimental conditions, data suggest that butyr-
olactone I-induced neuroprotection appears to be mainly due
to inhibition of cdk5. These data were supported by the e¡ects
of cdk5 antisense in reducing neuronal death promoted by
AL, as correlated with a decrease in the expression of this
kinase by around 50%. These ¢ndings suggest that cdk5 acti-
vation is a target in the process triggered by AL and that it
leads to neuronal degeneration and death.
On the other hand, data suggest that anomalous tau phos-
phorylations that appear to be derived from the AL-induced
activation of cdk5 could also be involved in neuronal alter-
ations that lead to cell death. These studies are also in agree-
ment with the idea that tau protein modi¢ed by the cdk5
system becomes sensitive to subsequent phosphorylations by
GSK3, a sequence of events in which neurodegeneration may
involve coordinated activation of both cdk5 and GSK3 sys-
tems [41].
In the context of this study, it is interesting to point out
that previous ¢ndings revealed that an activation of cdk5 in-
duces apoptosis in neuronal cells [42,43]. Thus, the marked
decrease in neuronal death caused by cdk5 inhibition by bu-
tyrolactone I or the cdk5 antisense could be related with its
reduction of apoptotic e¡ects. However, at this stage, it is
di⁄cult to ascertain how the changes in cdk5 promoted by
AL would contribute to neuronal death via alteration on the
cell cytoskeleton or by a direct e¡ect in stimulating the apop-
totic pathway or a combination of both phenomena. On the
other hand, the contribution of cytoskeletal alteration on the
sequence of events leading to neuronal death is strongly sup-
ported by the e¡ects of MT stabilizing drugs like paclitaxel in
protecting neurons against the neuro¢brillary pathology ob-
served in AD [44]. The involvement of cdk5 in the cytoskeletal
changes resulting after the abnormal phosphorylations on tau
is strongly supported by the presence of this protein kinase in
NFTs from AD brains [45]. Taken together all this informa-
tion, this study provides new clues to understand how ¢bril-
lary AL promotes hyperphosphorylations at tau epitopes re-
lated with AD and the involvement of cdk5, a component of
the TPK II system, in mediating the sequence of molecular
changes occurring in neurons a¡ected by the amyloid.
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